Fertility Treatment in Shanghai: IVF Options for International Patients

Infertility affects approximately one in six couples worldwide. For many, in vitro fertilization (IVF) and related assisted reproductive technologies (ART) represent the most effective path to parenthood. Shanghai has emerged as a significant destination for fertility treatment, with reproductive medicine centers at its major university hospitals offering advanced laboratory technology, experienced embryologists, and success rates that compare favorably with leading Western clinics. For international patients, the combination of clinical quality, shorter waiting times, and substantially lower costs makes Shanghai worth serious consideration.

This guide provides a detailed overview of the fertility treatment landscape in Shanghai, the IVF process, available technologies, regulatory considerations for foreign nationals, and what to expect as an international patient.

Understanding Infertility: Causes and Diagnosis

Infertility is defined as the failure to achieve a clinical pregnancy after 12 months of regular unprotected intercourse (or 6 months for women over 35). It affects both men and women in roughly equal measure: approximately one-third of cases are attributable to female factors, one-third to male factors, and one-third to combined or unexplained causes.

Female Causes

• Ovulatory dysfunction: The most common female cause, accounting for approximately 25% of infertility cases. Includes polycystic ovary syndrome (PCOS), hypothalamic amenorrhea, hyperprolactinemia, and premature ovarian insufficiency (POI). PCOS alone affects 8-13% of reproductive-age women globally.
• Tubal factor: Blocked or damaged fallopian tubes, most commonly due to prior pelvic inflammatory disease (PID), chlamydia infection, endometriosis, or previous pelvic surgery. Tubal factor infertility accounts for approximately 25-35% of female infertility.
• Endometriosis: A condition in which endometrial-like tissue grows outside the uterus, causing inflammation, adhesions, and distortion of pelvic anatomy. Present in 25-50% of infertile women. Affects fertility through multiple mechanisms including impaired egg quality, tubal damage, and altered uterine receptivity.
• Uterine factors: Submucosal fibroids, endometrial polyps, uterine septum, intrauterine adhesions (Asherman's syndrome), and congenital uterine anomalies can impair implantation and increase miscarriage risk.
• Diminished ovarian reserve (DOR): Reduced quantity and/or quality of eggs, assessed by antral follicle count (AFC) on ultrasound and serum anti-Mullerian hormone (AMH) level. DOR is more common with advancing age but can occur in younger women.
• Cervical factor: Hostile cervical mucus or cervical stenosis impeding sperm transport. Less commonly a primary cause of infertility in the era of IVF.

Male Causes

• Oligospermia: Low sperm count (below 16 million/mL per WHO 2021 reference values).
• Asthenospermia: Reduced sperm motility (below 42% total motility).
• Teratospermia: High proportion of abnormally shaped sperm (below 4% normal morphology by strict Kruger criteria).
• Azoospermia: Complete absence of sperm in the ejaculate. Classified as obstructive (blockage in the reproductive tract, often correctable) or non-obstructive (impaired sperm production). Surgical sperm retrieval (TESA, PESA, micro-TESE) can obtain sperm for ICSI in many cases.
• Sperm DNA fragmentation: High levels of DNA damage in sperm, associated with recurrent miscarriage and poor embryo development. Assessed by sperm DNA fragmentation index (DFI) testing.

Diagnostic Workup

A comprehensive fertility workup in Shanghai typically includes:

• Female: Day 2-3 FSH, LH, estradiol, AMH, prolactin, thyroid function (TSH, fT4), antral follicle count (AFC) by transvaginal ultrasound, hysterosalpingography (HSG) or saline infusion sonography (SIS) to assess tubal patency and uterine cavity, and diagnostic hysteroscopy or laparoscopy if indicated.
• Male: Semen analysis (WHO 2021 criteria), sperm DNA fragmentation index, hormonal profile (FSH, LH, testosterone, prolactin), scrotal ultrasound, and genetic testing (karyotype, Y-chromosome microdeletion, CFTR mutation screening for azoospermia).
• Both partners: Infectious disease screening (HIV, hepatitis B, hepatitis C, syphilis, rubella immunity), blood group and Rh factor, and karyotype if recurrent miscarriage or severe male factor.

Assisted Reproductive Technologies: An Overview

Ovulation Induction (OI)

For women with ovulatory dysfunction (particularly PCOS) and patent tubes, ovulation induction with oral agents (letrozole or clomiphene citrate) or low-dose gonadotropins, combined with timed intercourse or intrauterine insemination (IUI), is the first-line treatment. Letrozole has largely replaced clomiphene as the preferred agent for PCOS-related anovulation based on superior live birth rates demonstrated in the PPCOS II trial.

Intrauterine Insemination (IUI)

IUI involves placing washed, concentrated sperm directly into the uterine cavity around the time of ovulation, bypassing the cervix and reducing the distance sperm must travel. It is appropriate for mild male factor infertility, unexplained infertility, and cervical factor. Success rates per cycle are modest (10-20% per cycle in favorable cases) and decline with age. IUI is generally attempted for 3-6 cycles before proceeding to IVF if unsuccessful.

In Vitro Fertilization (IVF)

IVF is the most effective ART procedure. It involves stimulating the ovaries to produce multiple eggs, retrieving those eggs, fertilizing them in the laboratory, culturing the resulting embryos, and transferring one or more embryos into the uterus. The key steps are:

Step 1: Ovarian Stimulation

The woman self-administers daily subcutaneous injections of gonadotropins (FSH, LH, or combined preparations) for approximately 8-14 days to stimulate the development of multiple follicles. The response is monitored by serial transvaginal ultrasound (follicle tracking) and serum estradiol measurements, typically every 2-3 days. The stimulation protocol is individualized based on ovarian reserve, age, and prior response:

• GnRH agonist long protocol: Pituitary downregulation with a GnRH agonist (e.g., leuprolide) before stimulation begins. Provides excellent control but requires a longer treatment period. Historically the most widely used protocol.
• GnRH antagonist protocol: GnRH antagonist (e.g., cetrorelix, ganirelix) is added during stimulation to prevent premature LH surge. Shorter protocol, lower risk of ovarian hyperstimulation syndrome (OHSS), and allows GnRH agonist trigger. Now the preferred protocol at most centers.
• Mild/minimal stimulation IVF: Lower doses of gonadotropins or oral agents (letrozole, clomiphene) to retrieve fewer eggs with reduced medication burden and cost. Suitable for poor responders or patients preferring a gentler approach.
• Natural cycle IVF: No stimulation medications - the single naturally developing follicle is monitored and the egg retrieved. Very low success rate per cycle but avoids all stimulation risks. Rarely used except in specific circumstances.

Step 2: Trigger and Egg Retrieval

When follicles reach maturity (typically 17-20 mm in diameter), a trigger injection is administered to induce final egg maturation. Two trigger options exist:

• hCG trigger: Traditional trigger. Effective but carries higher OHSS risk in high-responders.
• GnRH agonist trigger: Used in antagonist protocols. Significantly reduces OHSS risk. Preferred in high-responders and when a freeze-all strategy is planned.

Egg retrieval (oocyte pick-up, OPU) is performed 34-36 hours after the trigger under transvaginal ultrasound guidance, with intravenous sedation or light general anesthesia. A needle is passed through the vaginal wall into each follicle to aspirate the follicular fluid containing the egg. The procedure takes approximately 15-30 minutes. Patients typically rest for 1-2 hours and are discharged the same day.

Step 3: Fertilization

Retrieved eggs are assessed for maturity and fertilized in the laboratory using one of two methods:

• Conventional IVF insemination: Mature eggs are placed in a dish with a prepared sperm sample and fertilization occurs naturally. Used when sperm parameters are normal or near-normal.
• Intracytoplasmic Sperm Injection (ICSI): A single sperm is injected directly into each mature egg using a fine glass needle under high-power microscopy. Used for male factor infertility, prior fertilization failure, surgically retrieved sperm, and increasingly as a routine approach at many centers. ICSI does not improve outcomes over conventional IVF when sperm parameters are normal.

Fertilization is confirmed 16-18 hours after insemination by the presence of two pronuclei (2PN). Fertilization rates with ICSI are typically 70-80%.

Step 4: Embryo Culture

Fertilized eggs (zygotes) are cultured in the laboratory for 3-6 days. Most centers now culture embryos to the blastocyst stage (day 5-6), as blastocysts have higher implantation potential than day-3 cleavage-stage embryos and allow better selection of the most viable embryos. Blastocyst culture requires a high-quality embryology laboratory with optimized culture media and incubator conditions.

Key embryo quality assessment parameters include:

• Morphological grading: Assessment of cell number, symmetry, fragmentation (cleavage stage) or inner cell mass and trophectoderm quality (blastocyst stage) under light microscopy.
• Time-lapse imaging (EmbryoScope): Continuous monitoring of embryo development without removing embryos from the incubator. Provides detailed developmental kinetics data and may improve embryo selection. Available at leading Shanghai IVF centers.
• Preimplantation Genetic Testing (PGT): Biopsy of 5-10 trophectoderm cells from the blastocyst for genetic analysis. See below for details.

Step 5: Embryo Transfer

One (or occasionally two) embryos are transferred into the uterine cavity through a thin catheter passed through the cervix under ultrasound guidance. The procedure is painless and takes approximately 5-10 minutes. No anesthesia is required. The number of embryos transferred is guided by age, embryo quality, and prior IVF history. Single embryo transfer (SET) is strongly recommended in most cases to minimize the risk of multiple pregnancy, which carries significant maternal and neonatal risks.

Embryo transfer can be performed in a fresh cycle (2-6 days after egg retrieval) or in a frozen-thawed embryo transfer (FET) cycle after cryopreservation. FET is increasingly preferred because:

• It allows the uterus to recover from stimulation before transfer
• It eliminates OHSS risk in high-responders
• It allows time for PGT results
• Cumulative evidence suggests equivalent or superior outcomes with FET compared to fresh transfer in many patient groups

Advanced Technologies Available in Shanghai

Preimplantation Genetic Testing (PGT)

PGT involves biopsy of blastocyst-stage embryos followed by genetic analysis before transfer. Three main applications:

• PGT-A (Aneuploidy): Screens embryos for chromosomal number abnormalities (aneuploidies such as trisomy 21, monosomy X). Identifies euploid (chromosomally normal) embryos for transfer. Most commonly used in women of advanced maternal age (AMA, typically 35+), recurrent implantation failure, and recurrent miscarriage. Performed using next-generation sequencing (NGS). Reduces miscarriage rates and may improve live birth rates per transfer, though its benefit in unselected populations remains debated.
• PGT-M (Monogenic disorders): Tests embryos for specific single-gene disorders for which one or both parents are carriers or affected. Examples include cystic fibrosis, spinal muscular atrophy (SMA), BRCA1/2 mutations, Huntington's disease, thalassemia, and sickle cell disease. Requires custom probe design specific to the family's mutation, typically taking 2-3 months of preparation before the IVF cycle.
• PGT-SR (Structural Rearrangements): Tests embryos from parents carrying chromosomal structural rearrangements (translocations, inversions) that increase the risk of unbalanced chromosomal complements in offspring.

PGT is available at Shanghai's leading reproductive medicine centers. The technology and laboratory standards are equivalent to those at top Western IVF clinics.

Surgical Sperm Retrieval

For men with azoospermia, sperm can be retrieved surgically for use with ICSI:

• PESA (Percutaneous Epididymal Sperm Aspiration): Fine needle aspiration of the epididymis. Used for obstructive azoospermia.
• TESA (Testicular Sperm Aspiration): Fine needle aspiration of the testis. Used for obstructive azoospermia when PESA is unsuccessful.
• Micro-TESE (Microsurgical Testicular Sperm Extraction): Microsurgical exploration of the testis under operating microscope to identify and extract sperm-producing tubules. The most effective technique for non-obstructive azoospermia, with sperm retrieval rates of 40-60% depending on the underlying cause. Available at Shanghai's major andrology and urology departments.

Frozen Embryo Transfer (FET) Protocols

FET can be performed in a natural cycle (monitoring the natural ovulation), a modified natural cycle (with hCG trigger), or a hormone replacement therapy (HRT) cycle (using exogenous estrogen and progesterone to prepare the endometrium). The optimal protocol depends on the patient's cycle regularity and clinical circumstances. Endometrial receptivity assessment tools - including endometrial thickness measurement, endometrial receptivity array (ERA) testing, and uterine natural killer cell assessment - are available at leading Shanghai centers for patients with recurrent implantation failure.

Fertility Preservation

Egg freezing (oocyte cryopreservation) using vitrification - an ultra-rapid freezing technique that prevents ice crystal formation - has become a reliable option for fertility preservation. Indications include:

• Medical fertility preservation before chemotherapy or radiotherapy that may damage ovarian function
• Elective (social) egg freezing for women wishing to delay childbearing
• Embryo banking across multiple IVF cycles to accumulate sufficient embryos before transfer

Vitrified egg survival rates exceed 90% at experienced centers, and pregnancy rates from vitrified eggs are now comparable to fresh eggs. Embryo vitrification (freezing fertilized embryos) has even higher survival rates and is the standard approach for surplus embryos after a fresh transfer cycle.

Regulatory Considerations for Foreign Nationals

This is an important area that international patients must understand before planning fertility treatment in China.

China's regulations on assisted reproduction are governed by the Ministry of Health's 2003 regulations on ART and sperm banks. Key points relevant to foreign nationals:

• Married couples only: IVF in China is legally restricted to married heterosexual couples. Single women and same-sex couples cannot access IVF at licensed Chinese hospitals. Proof of marriage (marriage certificate, typically requiring notarization and apostille for foreign documents) is required for registration.
• Donor eggs and sperm: Egg donation and sperm donation are permitted under Chinese regulations but are subject to strict controls. Anonymous donation is the standard. Waiting times for donor eggs can be significant. Regulations on cross-border gamete use are complex and should be clarified with the specific center.
• Surrogacy: Commercial surrogacy is prohibited in China. This guide does not address surrogacy arrangements.
• PGT regulations: PGT is permitted for medical indications (genetic disease prevention, recurrent miscarriage, recurrent implantation failure) at licensed centers. The regulatory framework for PGT-A in China has evolved and current practice should be confirmed with the treating center.
• Documentation requirements: Foreign couples typically need to provide passports, marriage certificate (with certified translation and notarization), and infectious disease screening results. Requirements vary by hospital and may change. CMCS can provide current guidance on documentation requirements for specific centers.

Regulations in this area are subject to change. It is essential to obtain current, center-specific guidance before making plans.

IVF Success Rates: What the Numbers Mean

IVF success rates are reported in multiple ways, and understanding the differences is important for realistic expectations:

• Clinical pregnancy rate per transfer: The proportion of embryo transfers resulting in a clinical pregnancy (fetal heartbeat confirmed on ultrasound at 6-8 weeks). Does not account for subsequent miscarriage.
• Live birth rate per transfer: The proportion of embryo transfers resulting in a live birth. The most clinically meaningful metric.
• Cumulative live birth rate: The probability of achieving a live birth from all embryos generated in a single egg retrieval cycle (including all fresh and frozen transfers). The most comprehensive measure of IVF effectiveness.

Success rates decline significantly with age, primarily due to the increasing proportion of chromosomally abnormal eggs with advancing age:

• Under 35: live birth rate per transfer approximately 40-50% (fresh or frozen euploid embryo)
• 35-37: approximately 35-45%
• 38-40: approximately 25-35%
• 41-42: approximately 15-25%
• Over 42: approximately 5-15% with own eggs; significantly higher with donor eggs

Shanghai's leading reproductive medicine centers report success rates in these ranges, consistent with top international clinics. When comparing success rates between centers, ensure you are comparing the same metric (live birth rate, not clinical pregnancy rate) and the same patient age group.

Ovarian Hyperstimulation Syndrome (OHSS)

OHSS is the most significant acute complication of IVF stimulation. It occurs when the ovaries over-respond to gonadotropin stimulation, leading to fluid shifts, ovarian enlargement, and in severe cases, ascites, pleural effusion, thromboembolism, and renal impairment. Risk factors include PCOS, young age, high AMH, and high antral follicle count.

Modern OHSS prevention strategies have dramatically reduced the incidence of severe OHSS:

• GnRH antagonist protocol (allows GnRH agonist trigger)
• GnRH agonist trigger instead of hCG trigger in high-responders
• Freeze-all strategy (no fresh transfer, eliminating the hCG of early pregnancy that exacerbates OHSS)
• Cabergoline (dopamine agonist) to reduce vascular permeability
• Intravenous albumin at egg retrieval in high-risk patients

Severe OHSS requiring hospitalization now occurs in less than 1% of IVF cycles at centers using these preventive strategies.

What Medical Records Are Required

To facilitate a fertility consultation in Shanghai, couples should prepare:

• Female: Recent hormone profile (FSH, LH, AMH, estradiol, prolactin, TSH - ideally within 6 months), transvaginal ultrasound report with antral follicle count, HSG or hysteroscopy report (if performed), any prior IVF cycle summaries (stimulation protocol, egg numbers, embryo grades, transfer outcomes), surgical reports (laparoscopy, myomectomy, etc.), and complete medical history.
• Male: Recent semen analysis (within 3-6 months), sperm DNA fragmentation index (if performed), hormonal profile, and any prior urological or andrological evaluations.
• Both: Infectious disease screening results, marriage certificate, and passports.

Cost Reference

IVF costs in Shanghai are substantially lower than in Western countries:

• Initial fertility consultation: USD 100-300
• Diagnostic workup (hormones, ultrasound, semen analysis): USD 300-800
• IVF cycle (stimulation medications + egg retrieval + laboratory + fresh transfer): USD 4,000-8,000
• Frozen embryo transfer (FET) cycle: USD 1,000-2,500
• ICSI (add-on to IVF): USD 500-1,500
• PGT-A (per embryo tested): USD 200-400
• PGT-M (custom probe design + testing): USD 2,000-5,000
• Micro-TESE: USD 3,000-6,000
• Egg freezing cycle (stimulation + retrieval + first year storage): USD 3,500-6,500

Comparable IVF cycles in the United States typically cost USD 15,000-25,000 per cycle (excluding medications). In the UK (private), USD 8,000-15,000. In Australia, out-of-pocket costs after Medicare rebates are typically AUD 5,000-10,000 per cycle.

Frequently Asked Questions

How many IVF cycles should I expect to need?
This depends heavily on age, ovarian reserve, and the underlying cause of infertility. Younger women with good ovarian reserve often achieve success in 1-2 cycles. Older women or those with diminished reserve may need more cycles or may not achieve success with their own eggs. A realistic discussion of prognosis based on individual factors should occur at the initial consultation.

Can I do the monitoring in my home country and only travel to Shanghai for egg retrieval?
Partial monitoring in the home country is sometimes possible for patients who cannot stay in Shanghai for the full 10-14 day stimulation period. This requires coordination between the Shanghai clinic and a local reproductive endocrinologist or gynecologist willing to perform monitoring scans and blood tests and share results in real time. CMCS can help facilitate this coordination.

How long do I need to stay in Shanghai for an IVF cycle?
For a fresh IVF cycle with fresh transfer: plan for approximately 3-4 weeks (initial consultation and baseline tests, stimulation monitoring, egg retrieval, embryo culture, and transfer). For a freeze-all strategy with FET in a subsequent cycle: the stimulation and retrieval phase requires approximately 2-3 weeks, and the FET cycle can be done in a separate trip of approximately 1-2 weeks.

What happens to frozen embryos if I return home?
Frozen embryos can be stored at the Shanghai clinic for subsequent FET cycles during future visits. International embryo transport (shipping frozen embryos to a clinic in your home country) is technically possible but involves complex logistics, regulatory requirements in both countries, and significant cost. This should be discussed with both the Shanghai clinic and your home country clinic before proceeding.

Is the quality of IVF laboratories in Shanghai comparable to Western clinics?
Shanghai's leading reproductive medicine centers - including those at Renji Hospital, Ruijin Hospital, and the International Peace Maternity and Child Health Hospital - operate IVF laboratories with modern equipment, quality control systems, and embryology teams trained to international standards. Success rates at these centers are consistent with top-tier Western clinics for equivalent patient populations.

Begin Your Fertility Journey in Shanghai

If you are considering IVF or other fertility treatments in Shanghai, China Medical Concierge (CMCS) can help identify the right reproductive medicine center for your situation, coordinate your consultation and documentation, and support your stay from arrival to departure. Contact us for a confidential initial discussion.